
    
      Adult participants with a diagnosis of HeFH or CHD or multiple risk factors (â‰¥2) and with
      primary hypercholesterolemia who had successfully completed the 14-week, double-blind
      efficacy and safety study of ezetimibe co-administered with atorvastatin (Protocol No.
      P00693/MK-0653-030; NCT03867318) were eligible for enrollment in this long-term extension
      study.
    
  